Company: RGBP
Filing Date: 2025-02-24
Form Type: 253G1
Source: 0001493152-25-008067
Chunk: 30

Company: Regen BioPharma Inc
Filing Date: 2025-02-24
Form: 253G1
Chunk 30
---
ments likelihood of successful induction of immunity.

Patent No. 11,090,332

METHOD OF CANCER TREATMENT USING SIRNA SILENCING

Comprises administering to a subject one or more siRNA constructs capable of inhibiting the expression of an immunosuppressive molecule. The invention also provides siRNA constructs and compositions.

Patent No: 8389708

SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN HUMANS.

Patent No. 11,324,719

The invention relates to compounds useful to alteration of NR2F6 activity.

Patent No. 11,712,474

Means of stimulating systemic immunity and reduction of post-surgery tumor metastasis through the concurrent intralymphatic inhibition of NR2F6 and treatment with cannabidiol. Through the combination of immunogenic cell death and immune stimulation, the invention provides a means of enhancing the abscopal effect and in some embodiments to cause immunological mediated destruction primary and secondary neoplasia.

Patent No. 11,241,427

Compounds useful for alteration of NR2F6 activity.

| 26 |

Patent no. 11,655,474

Means, methods and compositions of matter useful for suppressing pathological production of new blood vessels in conditions such as cancer and wet macular degeneration. In one embodiment the invention provides silencing of NR2F6 using nucleic acid based approaches such as RNA interference, antisense oligonucleotides, or DICER. In another embodiment, the invention teaches the administration of small molecule NR2F6 inhibitors as means of selectively inhibiting pathological but not healthy angiogenesis.

Active Patent Applications:

| Title                                                                                                                                        |     | Application Number |             |
| Enhancement Of Chimeric Antigen Receptor T Cell Efficacy By Dedifferentiation                                                                |     |                    |    18447150 |
| Enhanced Dendritic Cell Immune Activation By Combined Inhibition Of NR2F6 With Cannibidiol                                                   |     |                    |    62882931 |
| Immune Modulation By TLR Activation For Treatment Of Filovirus Infections Including Ebola                                                    |     |                    |    14954902 |
| Nr2f6 Silenced Autologous Immunotherapeutics                                                                                                 |     |                    |    15299400 |
| Treatment Of Liver Cancer Through Embolization Depot Delivery Of BORIS Gene Silencing Agents                                                 |